Evotec
Evotec SE is a German drug discovery and development alliance company providing drug discovery solutions for biopharmaceutical partners. The company operates integrated research platforms spanning target identification, hit identification, lead optimization, and pre-clinical development. Revenue is generated through research fees, licensing agreements, collaborative milestone payments, and commercial royalty sharing with biopharmaceutical partners. Core end markets embrace global pharmaceutical corporations, biotechnology startups, academic research centers, and disease foundations. Evotec holds a market-leading position in Europe as an outsourced drug discovery platform partner for the life sciences sector. The company is headquartered in Hamburg, Germany, and its shares are listed on the Frankfurt Stock Exchange and the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Evotec.
- Legal name
- Evotec AG
- Sector
- Health Care
- Country
- Germany
- Funds holding it
- 3
Funds holding Evotec
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)